Inspirational Women in STEM and Tech: Dr. Christina Smolke of Antheia On The 5 Leadership Lessons She Learned From Her Experience As a...

Synthetic biology attracted $8.9 billion in venture funding during the first half of 2021, according to synbio stakeholder group...

Antheia is at a critical point in scaling our production technology. Just as we bring together exceptional science and technologies to...

Antheia – Zack McGahey was named COO and will be responsible for all operations functions as the company scales and commercializes its...

Antheia CEO Christina Smolke brews up new pharmaceuticals. Watch the video interview at nbcbayarea.com

Synthetic biology isn’t a household name - yet. But it will be soon, because it’s a thriving, innovative field that’s solving some of...

Ginkgo Bioworks, a Boston-based cell-programming specialist, will deploy its high-throughput enzyme design and screening technology to...

Antheia reconstructs complex biochemical pathways in yeasts to speed up production of natural product-based drugs Read the article at:...

California synthetic biology firm Antheia has joined forces with Boston-based biotech company Ginkgo Bioworks to strengthen its efforts...

Antheia Inc., of Menlo Park, Calif., and Ginkgo Bioworks Inc., of Boston, are partnering to accelerate development and production of...

With supply chain shortages at the forefront of nearly every business in the world right now, whether it be chicken wings or CAR-T cell...

Fundraising at Bota Bio, Genomatica, and Antheia signals an upshift for commercial-scale synthetic biology Read the article at:...

Antheia, a synthetic biology company cofounded and led by Stanford University bioengineer Christina Smolke, has raised $73 million in...

Antheia, a synthetic biology company working to develop plant-inspired medicine, has officially secured a fresh $73 million in Series B...

Synthetic biology startup Antheia raised $73 million in Series B financing to support the company’s efforts to bring its first...

The idea: A California company producing active pharmaceutical ingredients with engineered yeast raised $73 million to bring its first...

Antheia, a Menlo Park CA-based synthetic biology company, raised $73M in Series B funding. The round was led by Viking Global Investors...

Led by Viking Global Investors, the Series B round will be used to bring Antheia's first pharmaceutical compounds to market, expand its...

Antheia Inc., a startup using synthetic biology to produce medicines currently sourced from plants, has raised $73 million in new...

The age of synthetic biology is officially upon us with super-unicorns like Ginkgo Bioworks changing the game in terms of how investors...